Closing the last-mile gap in personalised medicine

Where personalised medicine becomes deliverable.

Personalised medicine is creating new possibilities for earlier diagnosis, targeted treatment, trial matching, risk-based prevention and more precise care. But scientific progress does not automatically become patient access. IPM Alliance focuses on the harder question: whether health systems are ready to identify eligible patients, activate the right pathways and deliver better care in time.

See more

The core problem

Science-rich. Pathway-poor.

Across oncology, rare diseases, cardiovascular and cardiometabolic disease, obesity and metabolic disease, immunology, neurology, diagnostics, biomarkers, AI-enabled healthcare and clinical trials, scientific progress is creating new opportunities for patients. Yet many systems still struggle to translate those opportunities into routine care. Diagnostic capacity may be uneven. Reimbursement may lag. Referral pathways may be fragmented. Data systems may not connect. Workforce capacity may be limited. Geography may decide who benefits first, late or not at all.

“Scientific progress creates eligibility. System readiness determines access.”

 

Scientific progress creates possibility

  • New diagnostics
  • Biomarkers
  • Targeted therapies
  • AI-enabled tools
  • Trial matching
  • Risk-based prevention

System gaps delay delivery

  • Uneven testing capacity
  • Reimbursement delays
  • Fragmented referral
  • Weak data infrastructure
  • Workforce shortages
  • Regional inequality

The IPM Answer

Implementation intelligence for personalised medicine

IPM Alliance is an international platform for personalised medicine implementation. It connects evidence, policy, access, stakeholder intelligence and practical delivery tools to help health systems understand where personalised medicine is ready, where it is blocked and what needs to change.

Intelligence

Signals, Alerts, Briefs and policy monitoring that explain what changed, why it matters and what should be watched next.

Disease Desks

Structured disease-specific intelligence on readiness, access, diagnostics, biomarkers, screening, care pathways and equity.

Stakeholder Insight

Analysis of how policymakers, clinicians, patients, payers, researchers, diagnostics leaders and innovators experience implementation barriers.

Implementation Labs

Multi-stakeholder sessions that turn access problems into prototypes, roadmaps, practical recommendations and follow-up actions.